Whereas more than 52 million people in the U.S. are affected by some form of arthritis, hope lies in the 92 innovative new medicines in development to treat it. This infographic from PhRMA brings you the details.
America’s biopharmaceutical research companies are developing 92 innovative new medicines to help the millions of Americans affected by arthritis. New medicines today in the research and development pipeline offer hope of reducing the human and economic costs of the many musculoskeletal disorders affecting Americans. These medicines—all either in clinical trials or under review by the U.S. Food and Drug Administration—include:
- 55 for rheumatoid arthritis, which affects an estimated 1.5 million American adults;
- 15 for musculoskeletal pain, which affects the muscles, ligaments, tendons, and bones. Approximately 15 million adults report that they are unable to perform some common activities due to the pain;
- 10 for osteoarthritis, the most common form of arthritis, which affects nearly 27 million Americans; and
- 7 for psoriatic arthritis, an inflammatory arthritis, which affects approximately 30 percent of people with psoriasis.